1. Home
  2. TPCS vs RNTX Comparison

TPCS vs RNTX Comparison

Compare TPCS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TechPrecision Corporation Common stock

TPCS

TechPrecision Corporation Common stock

N/A

Current Price

$4.49

Market Cap

44.9M

Sector

Industrials

ML Signal

N/A

RNTX

Rein Therapeutics Inc. Common Stock

HOLD

Current Price

$1.42

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPCS
RNTX
Founded
1956
2001
Country
United States
United States
Employees
N/A
11
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.9M
38.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TPCS
RNTX
Price
$4.49
$1.42
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
53.3K
2.6M
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$33,564,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.15
N/A
52 Week Low
$2.05
$1.04
52 Week High
$6.25
$3.50

Technical Indicators

Market Signals
Indicator
TPCS
RNTX
Relative Strength Index (RSI) 46.43 48.54
Support Level $4.41 $1.15
Resistance Level $4.70 $1.58
Average True Range (ATR) 0.30 0.12
MACD 0.03 0.00
Stochastic Oscillator 39.33 58.14

Price Performance

Historical Comparison
TPCS
RNTX

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: